89bio's SWOT analysis: pegozafermin's potential in MASH and SHTG markets
Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
89bio's Pegozafermin Is Now Gaining Momentum
Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...
Why 89bio Stock Lagged the Market Today
(NASDAQ: ETNB) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of ...
Best, worst of biotech times: One company soars, another stumbles and a third seeks funds
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...
89bio stock rallies 40% amid data for rival MASH drug
(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...
Akero soars as drug shows it reverses scarring in liver disease patients
Akero Therapeutics shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.